Lenvatinib Mesylate Intermediate CAS 15568-85-1 daahirnimo>97.0% (HPLC) Warshada
Qalabka Kiimikada ee Ruifu Lenvatinib Mesylate Dhexdhexaadiyeyaasha oo leh nadiif sare
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Magaca Kiimikada | 5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion |
La mid ah | 5-(Methoxymethylene) Asiidhka Meldrum;Cabozantinib wasakhnimo 56;Lenvatinib wasakh 79 |
Lambarka CAS | 15568-85-1 |
Lambarka CAT | RF-PI1967 |
Heerka Saamiyada | Kaydka dhexdiisa, Qiyaasta Waxsoosaarka Ilaa Tan |
Qaanuunka molecular | C8H10O5 |
Miisaanka Molecular | 186.16 |
Meesha dhalaalaysa | 132.0 ~ 134.0 ℃ |
Cufnaanta | 1.297± 0.06 g/cm3 |
Summada | Kiimikada Ruifu |
Shayga | Tilmaamaha |
Muuqashada | Budada jaalaha ah |
1 H NMR Spectrum | Waafaqsan Qaab-dhismeedka |
Daahirnimada / Habka Falanqaynta | > 97.0% (HPLC) |
Wadarta wasakhda | <3.00% |
Heerka Imtixaanka | Heerka Ganacsiga |
Isticmaalka | Dhexdhexaadiyaha Lenvatinib Mesylate (CAS: 857890-39-2) |
Xidhmada: Dhalo, bacda bireed aluminium, 25kg / Durbaan kartoonada, ama sida waafaqsan shuruudaha macmiilka
Xaaladda Kaydinta:Ku kaydi weelasha xiran meel qabow oo qallalan;Ka ilaali iftiinka iyo qoyaanka
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS: 15568-85-1) waa dhexdhexaad ah Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib waa dawada kansarka qanjirka tayroodhka oo ay soo saartay Eisai Corporation of Japan (Code: E7080), oo iska leh xannibaadaha tyrosine kinase ee afka laga qaato (RTK) waxayna joojin kartaa dhaqdhaqaaqa kinase ee xuubka kobaca endothelial vascular VEGFR1 (VEGF). FLT1), VEGFR2 (KDR), iyo VEGFR3 (FLT4).Lenvatinib waxa kale oo uu joojin karaa ku lug lahaanshaha RTK-yada kale ee angiogenesis-ka pathological, koritaanka burooyinka, iyo horumarka kansarka marka laga reebo hawlahooda gacanta ee caadiga ah oo ay ku jiraan fayraska koritaanka fibroblast (FGF) receptors FGFR1, 2, 3, iyo 4;Soo-dhoweeyaha korriinka ee platelet-derived (PDGFR [alpha]), KIT, iyo RET.[Tilmaanta]: Lenvatinib waxay ku habboon tahay daaweynta bukaannada kansarka tayroodh ee soo noqnoqda deegaanka ama nooca metastasis, nooca horumarka iyo shucaaca iodine-refractory nooc kala duwan.Febraayo 13, 2015, US FDA waxay ansixisay dawada ka hortagga kansarka ee Lenvatinib si loogu daweeyo kansarka tayroodhka.Lenvatinib waa inhibitor-bartilmaameedka enzyme-ka badan, isagoo awood u leh inuu xakameeyo VEGFR2 iyo VEGFR3 (receptor endothelial factor factor receptor).Magaca ganacsiga ee Lenvatinib waa Lenvima.Maajo 20, 2015, Hay'adda Daawooyinka Yurub (EMA) ayaa u ogolaatay Lenvatinib daawaynta caabuqa, gudaha hore u maray ama kala-duwanaanta metastatic (papillary, follicular, nooca Hurthle) kansarka tayroodhka (DTC).Tijaabada dhexdeeda, wakhtiga badbaadada dhexdhexaadka ah ee bukaanada DTC shucaaca iodine-refractory ee lagu daweeyay Lenvatinib waxay ahayd 18 bilood halka qiimaha bukaanada qaata placebo ay tahay 3 bilood oo keliya.